Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial.

Publication

Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial.

Journal Paper/Review - Nov 10, 2023

Balali Pargol, Hart Robert G, Smith Eric Edward, Saad Feryal, Colorado Pablo, Lemmens Robin, De Marchis Gian Marco, Caso Valeria, Xu Lizhen, Heenan Laura, Connolly Stuart J, Mundl Hardi, Shoamanesh Ashkan

Citation

Balali P, Hart R, Smith E, Saad F, Colorado P, Lemmens R, De Marchis G, Caso V, Xu L, Heenan L, Connolly S, Mundl H, Shoamanesh A. Cerebral Microbleeds and Asundexian in Non-cardioembolic Ischemic Stroke: Secondary Analyses of the PACIFIC-STROKE Randomized Trial. Int J Stroke 2023:17474930231216339.

Type

Journal Paper/Review (English)

Journal

Int J Stroke 2023

Publication Date

Nov 10, 2023

Issn Electronic

1747-4949

Pages

17474930231216339

Brief description/objective

Cerebral microbleeds are MRI markers of hemorrhage-prone cerebral small-vessel disease that predict future risk of ischemic stroke and intracranial hemorrhage (ICrH). There exists concerns about the net benefit of antithrombotic therapy in patients with microbleeds. We aimed to investigate the effects of an oral factor-XIa inhibitor (asundexian), that is hypothesized to inhibit thrombosis without compromising hemostasis, on the development of new microbleeds over time and interactions between microbleeds and asundexian treatment on clinical outcomes. We additionally assessed associations between baseline microbleeds and the risks of clinical and neuroimaging outcomes in patients with non-cardioembomic ischemic stroke.